HLA-A and neoplasm: The tumor weights at the end of experiments (mean and median tumor weight) of all animals receiving STEAP1130/HLA-A*02:01-specific TCR transgenic T cells (tgCD4, tgCD8, and tgCD4 plus tgCD8 T cells) were lower compared to the non-specific PBMC control group.